| News
Engimmune Therapeutics banks 15.5 million Swiss francs
03.05.2022
Engimmune Therapeutics will now be in a position to drive forward its innovative platforms for the development of T-cell therapies against cancer after receiving seed financing to the tune of 15.5 million Swiss francs. The company was founded and built up with the help of the biotech accelerator and incubator BaseLaunch.

Engimmune Therapeutics has received investments totaling 15.5 million Swiss francs for the development of novel T-cell receptor (TCR) therapeutics to combat cancer. The Basel-based biotech firm is a spin-off from the Department for Biosystems Science and Engineering (D-BSSE), likewise based in Basel, of the Swiss Federal Institute of Technology in Zurich (ETH). The company was incubated and initially financed via BaseLaunch, an incubator and accelerator operated by the investment and innovation promotion agency Basel Area Business & Innovation.
The seed financing round that has now closed was led by the Swiss venture capital fund Pureos Bioventures, a BaseLaunch partner, and Novo Seeds, the early-stage investment and company creation team of the Danish firm Novo Holdings. The gross proceeds from this financing round are, according to a press release, to be put towards further expanding the Engimmune pipeline, bolstering the research team in Switzerland and gaining a foothold in the Danish market.
Long-standing support from BaseLaunch
Engimmune has also announced the appointment of TCR pioneer and industry veteran Dr. Bent Jakobsen as Chairman of the Board. As part of the transaction, Dominik Escher and Jørgen Søberg Petersen will join the company as Board Directors, while Ximing Ding and João Ribas will join as observers.
“The long-standing support from BaseLaunch together with these industry-leading investors and the in-depth expertise of Bent gives Engimmune the standing to become a leading contributor to this competitive yet promising space”, explains Søren Mouritsen, CEO of Engimmune, in the press release.
“It was a real privilege to work alongside the team at Engimmune to help build the company from scratch”, comments Stephan Emmerth, BaseLaunch Director, in the press release. This group of investors will enable the company “to continue developing their pioneering technology platforms to deliver truly differentiated TCR therapeutics”, he adds.
Share this article
Sign up to receive our newsletter in your inbox.
You may also be interested in
VectivBio sold for approximately 1 billion dollars
The takeover of VectivBio is now being finalized: the Boston-based firm Ironwood Pharmaceuticals, which specializes in gastrointestinal medicine, has agreed...
Read MoreUniversity of Basel and RocketVax present new Covid vaccine
Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech...
Read MoreRami Swiss and Elbit Systems now manufacturing in Jura
The newly established company Rami Swiss has inaugurated a new production facility in Courtételle in the canton of Jura together...
Read MoreBasel to become Europe’s Silicon Valley of biotech
Silicon Valley is synonymous with technology and innovation, and home to dozens of Fortune 1000 companies and thousands of startups....
Read MoreRoche and Novartis among global leaders for research spending
In 2022, Roche invested 16 billion euros in research and development overall. This puts the Basel-based life sciences firm in...
Read MoreRoche to found Institute for Human Biology
Roche has announced that it will be establishing the Institute of Human Biology in Basel. Up to 250 employees will...
Read More